8-K: Achieve Life Sciences CMO Resigns, Transitions to Consultant

Achieve Life Sciences' Chief Medical Officer and President, Dr. Cindy Jacobs, has resigned, transitioning to a consulting role until FDA NDA approval for cytisinicline, with severance and accelerated equity vesting.

Summary

• Dr. Cindy Jacobs resigned from her roles as Chief Medical Officer and President of Achieve Life Sciences, Inc., effective October 6, 2025.
• The Company and Dr. Jacobs entered into a Separation Agreement and a Consulting Agreement on October 6, 2025.
• Dr. Jacobs will continue as a consultant until the U.S. Food and Drug Administration (FDA) approves the Company's New Drug Application (NDA) for cytisinicline.
• During her consultancy, Dr. Jacobs' existing equity awards will continue to vest, and she will receive compensation as outlined in the Consulting Agreement.
• She will receive a lump-sum cash severance payment of $101,296, representing a prorated portion of her 2025 target bonus.
• Upon termination of her consultancy (following NDA Approval), the full unvested portion of her time-based option grants from January 2023 and January 2024 will vest immediately.
• The post-termination exercise period for these options will be extended to twelve months following her consultancy termination.
• The Company will reimburse Dr. Jacobs up to $10,000 for legal fees related to the negotiation and preparation of the agreements.

Sentiment

Score: 5

Explanation: The departure of a key executive is generally a negative event, but the structured transition to a consulting role for a critical project (NDA) mitigates some of the immediate negative impact, resulting in a neutral to slightly negative sentiment.

Positives

• Retaining Dr. Jacobs as a consultant ensures continuity of her expertise, which is crucial for the ongoing cytisinicline NDA process.
• The structured separation plan minimizes immediate disruption to key operations and leadership.

Negatives

• The Company is losing a key executive from a full-time leadership role as Chief Medical Officer and President.
• The severance payment of $101,296 and up to $10,000 in legal fee reimbursements represent a financial cost to the Company.

Risks

• The departure of a key executive like the Chief Medical Officer and President could impact leadership stability and strategic direction.
• The Company's reliance on Dr. Jacobs as a consultant for the critical cytisinicline NDA approval process introduces a dependency.
• Any unforeseen issues or delays in the FDA's approval of the cytisinicline NDA could significantly impact the Company's future.

Future Outlook

The Company's future outlook is closely tied to the U.S. Food and Drug Administration's approval of its New Drug Application for cytisinicline, which is a key milestone determining the duration of Dr. Jacobs' consultancy and the finalization of her separation terms.

Industry Context

Executive transitions are common in the biopharmaceutical industry, particularly for companies with drugs in late-stage development. Retaining key personnel in a consulting capacity during critical regulatory phases, such as an NDA review, is a strategy often employed to maintain continuity of expertise.

Management Changes

Stakeholder Impact

• Shareholders: Potential impact on company stability and strategic direction due to executive change, but mitigated by retaining expertise for NDA.
• Employees: Potential for shifts in leadership and organizational structure following the departure of a key executive.
• Dr. Jacobs: Receives severance, continued equity vesting, and legal fee reimbursement as part of the separation.

Next Steps

• Dr. Jacobs will continue to serve as a consultant until the FDA approves the NDA for cytisinicline.
• The Separation Agreement and Consulting Agreement will be filed as exhibits to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Achieve Life Sciences, ACHV, Dr. Cindy Jacobs, Chief Medical Officer, President, resignation, executive change, cytisinicline, FDA, NDA, severance, equity vesting, consulting agreement